Biotest AG, DE0005227235

Biotest AG, DE0005227235

19.07.2017 - 07:03:20

Biotest AG: Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic

PRESS RELEASE

Biotest takes over Cara Plasma s.r.o. with one plasma collection centre in the Czech Republic

- Long-term plasma supplier Cara Plasma was taken over by Biotest

- Biotest has now 16 plasma collection centres in Europe and

- 22 stations in the USA for the strategic safeguarding of plasma supply

Dreieich, 19 July 2017. Today, Biotest took over its long-time plasma supplier Cara Plasma s.r.o. and thus increased the number of plasma centres in Europe to 16.

With Cara Plasma Biotest purchased a station in the Czech capital Prague and will further increase the plasma self-sufficiency rate.

"The additional station in the Czech Republic gives us the opportunity to secure the supply for our production facilities with plasma. We are raising the good and trustworthy cooperation with our long-term partner and current supplier Cara Plasma to a new stage." stated Dr. Martin Reinecke, Head of Plasma Alliances and Protein Supply.

The collected plasma is processed exclusively at Biotest AG, Dreieich, Germany. Audits conducted regularly in the Czech Republic ensure that high legal and internal quality requirements are met.

Biotest's strategic goal is to increase the share of plasma from its own centres in the future. At the same time Biotest is striving for a balanced supply of plasma from Europe and the USA.

About human blood plasma Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.

About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact Dr. Monika Buttkereit phone: +49-6103-801-4406 email: investor_relations@biotest.de

PR contact Dirk Neumüller phone: +49-6103-801-269 email: pr@biotest.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Prime Standard Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

19.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: Biotest AG Landsteinerstraße 5 63303 Dreieich

Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

593617  19.07.2017 

@ dgap.de